PAIGE BENNETT: Open Payments
NPI 1356019285 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,410 in 114 payments from 18 companies in 2025. Trend: 2023 $1,565 · 2024 $1,131 · 2025 $2,410
Food & beverage: $2,410
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $416 |
| E.R. Squibb & Sons, L.L.C. | 17 | $368 |
| Neurocrine BioSciences, Inc. | 15 | $295 |
| Teva Pharmaceuticals USA, Inc. | 8 | $272 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $237 |
| Supernus Pharmaceuticals, Inc. | 5 | $199 |
| Corium, LLC | 7 | $187 |
| Lundbeck LLC | 5 | $105 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
Products named: VRAYLAR, COBENFY, INGREZZA, AUSTEDO XR, CAPLYTA, Qelbree, Azstarys, REXULTI.
Industry payments across TX — which companies pay providers there.
